Enliven Therapeutics Inc. (ELVN)
Who owns Enliven Therapeutics Inc. (ELVN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 74.6% of the shares are freely tradable; institutional investors hold 89.7%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Orbimed Advisors, LLC | 13.07 | 7,959,538 | +0.0 | 03/31/2026 |
| FMR Inc | 11.21 | 6,829,246 | -3.9 | 03/31/2026 |
| Polar Capital Holdings PLC | 8.32 | 5,065,933 | +44.2 | 03/31/2026 |
| BlackRock Inc | 6.05 | 3,684,707 | +2.0 | 03/31/2026 |
| COMMODORE CAPITAL LP | 5.38 | 3,275,000 | -30.2 | 03/31/2026 |
| Vestal Point Capital LP | 5.34 | 3,250,000 | -15.1 | 03/31/2026 |
| Vanguard Group Inc | 4.60 | 2,801,665 | +9.7 | 12/31/2025 |
| Bellevue Group AG | 3.81 | 2,320,867 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.56 | 2,168,162 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Polar Capital Healthcare Opports Inc | 4.59 | 2,796,934 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 17. Jul 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 123 | 53.87 | 6,626 |
| 17. Jul 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 2,638 | 53.38 | 140,823 |
| 17. Jul 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 2,564 | 52.32 | 134,143 |
| 17. Jul 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 369 | 51.48 | 18,997 |
| 17. Jul 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Sell | 324 | 49.97 | 16,191 |
| 17. Jul 2026 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | Other | 1,072 | 2.48 | 2,659 |
| 17. Jul 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 63 | 53.92 | 3,397 |
| 17. Jul 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 2,184 | 53.42 | 116,669 |
| 17. Jul 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 2,063 | 52.39 | 108,085 |
| 17. Jul 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 459 | 51.55 | 23,660 |
| 17. Jul 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Sell | 231 | 50.05 | 11,563 |
| 17. Jul 2026 | Collins Helen Louise | CHIEF MEDICAL OFFICER | Other | 5,000 | 2.48 | 12,400 |
| 6. Jul 2026 | Kunkel Lori Anne | Director | Sell | 5,889 | 50.84 | 299,421 |
| 6. Jul 2026 | Kunkel Lori Anne | Director | Sell | 4,111 | 49.98 | 205,482 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.